Marshall Wace’s Adaptive Biotechnologies ADPT Stock Holding History

Marshall Wace’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.2M	Sell	86,347 -25,948	-23%	-$413K	﹤0.01%	2043
2025 Q4	$1.82M	Buy	+112,295	New	+$1.83M	﹤0.01%	1623
2023 Q1	–	Sell	-370,471	Closed	-$2.83M	–	2597
2022 Q4	$2.83M	Sell	370,471 -61,999	-14%	-$482K	0.01%	1533
2022 Q3	$3.08M	Sell	432,470 -254,794	-37%	-$2.4M	0.01%	1728
2022 Q2	$5.56M	Sell	687,264 -238,254	-26%	-$2.09M	0.01%	1261
2022 Q1	$12.8M	Buy	925,518 +845,225	+1,053%	+$13.3M	0.02%	705
2021 Q4	$2.25M	Buy	+80,293	New	+$2.46M	﹤0.01%	1970
2021 Q2	–	Sell	-170,442	Closed	-$6.86M	–	2602
2021 Q1	$6.86M	Buy	+170,442	New	+$9.23M	0.03%	651
2019 Q4	–	Sell	-2,444	Closed	-$76K	–	1650
2019 Q3	$76K	Buy	+2,444	New	+$99.7K	﹤0.01%	1425

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marshall Wace's ADPT Position: Q1 2026 in Review

Marshall Wace reduced its Adaptive Biotechnologies (ADPT) stake by 23% in Q1 2026, selling an estimated $413K and leaving 86,347 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2043.

Marshall Wace first reported a position in ADPT in Q3 2019 and has held it in 9 quarters since. The position peaked at $12.8M in Q1 2022. 295 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

Marshall Wace held 86,347 shares of Adaptive Biotechnologies worth $1.2M as of Q1 2026.
Marshall Wace sold 25,948 Adaptive Biotechnologies shares in Q1 2026, an estimated $413K.
Adaptive Biotechnologies made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2043 holding.
Marshall Wace first reported a position in Adaptive Biotechnologies in Q3 2019 and has held it in 9 quarters since.
Marshall Wace's Adaptive Biotechnologies position peaked at $12.8M in Q1 2022.
295 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.